Article
The first generic version of Accutane (isotretinoin), approved Nov. 11 by the FDA, reached market in late November at a price approximately 5.5 percent lower than the brand name.
Reflecting on the Growth of NPs and PAs in Dermatology
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Bridging Therapeutic Innovation and Dermatology
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin
Study Reveals Immune Checkpoint Inhibitor Treatment and Monitoring Practices Post-Remission